Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaOmid Hamid, Antoni Ribas, Wen-Jen Hwu et al.|New England Journal of Medicine|2013Cited by 3.4k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialCaroline Robert, Adil Daud, Antoni Ribas et al.|The Lancet|2014Cited by 1.8k